Accuracy and variability of locoregional staging in T1 rectal cancer: nationwide multicentre cohort study

T1期直肠癌局部区域分期的准确性和变异性:一项全国多中心队列研究

阅读:2

Abstract

BACKGROUND: Accurate locoregional staging is critical in the management of T1 rectal cancer and guides organ-preserving strategies. Despite guideline recommendations, the real-world performance of magnetic resonance imaging (MRI) and endoscopic ultrasound (EUS) remains unclear. This study aims to evaluate the use and accuracy of locoregional staging in T1 rectal cancer. METHODS: Retrospective analysis was performed from a nationwide multicentre T1 colorectal cancer cohort (EpiT1 Consortium) between 2007 and 2018 with a 5-year follow-up. Locoregional staging methods included MRI and EUS. Multivariable logistic regression identified factors associated with locoregional imaging. The accuracy of each technique and their combination for T and N staging was assessed. RESULTS: Among 3161 patients with T1 colorectal cancer, 681 had rectal cancer, of which 424 (62.3%) underwent locoregional staging: 234 (55.2%) with MRI only, 131 (30.9%) with both MRI and EUS, and 59 (13.9%) with EUS only. Factors associated with imaging (MRI and EUS) included management at a referral centre (odds ratio 2.9, 95% confidence interval 1.5 to 5.7), tumour location in the low/middle rectum (odds ratio 3.2, 1.8 to 5.7), suspicion of invasive carcinoma at colonoscopy (odds ratio 2.4, 1.3 to 4.5), and high-risk histological features (odds ratio 3.7, 1.8 to 7.4). MRI accurately staged T in 28.3%, whereas EUS achieved an accuracy of 59% for T staging. Combining modalities overstaged 67.1% of tumours for T staging. N staging was detected with ≤ 16% sensitivity across all strategies; in the surgical group (MRI and/or EUS), overall accuracy was 78%. CONCLUSION: Locoregional staging varied widely and was influenced by non-tumour-related factors. MRI and EUS showed modest accuracy, overstaging T, and low sensitivity for N. These findings highlight the need to improve pretreatment evaluation of T1 rectal cancer.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。